Novel tau biomarkers for presymptomatic Alzheimer’s disease
November 2020
Barcelonaβeta Brain Research Center (BBRC), Barcelona, Spain(1)
University of Gothenburg, Gothenburg, Sweden(2)
University of Gothenburg, Gothenburg, Sweden(2)
The researchers have found three new forms of the tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop and can be thus used as diagnostic biomarkers. The scientists developed new tools to detect these subtle changes and confirmed their results in two studies with 381 and 503 human participants, respectively. The findings are also important for the testing of therapies against Alzheimer's disease.
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
José Luis Molinuevo(1), Kaj Blennow(2)
Marc Suárez‐Calvet et al. EMBO Molecular Medicine 2020 [1]
Bionity [2]
Thomas K. Karikari et al. Alzheimer's & Dementia 2020 [3]
Added on: 01-29-2021
[1] https://www.embopress.org/doi/full/10.15252/emmm.202012921[2] https://www.bionity.com/en/news/1168999/new-tests-identify-very-early-changes-in-alzheimer-s-disease-before-symptoms-appear.html[3] https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12236
